Akari Therapeutics (AKTX) Short-Term Debt repayments (2024 - 2026)
Akari Therapeutics recorded quarterly Short-Term Debt repayments of $102000.0 in Q1 2026, up 78.95% quarter-over-quarter from $57000.0 in Q4 2025, and down 5.56% year-over-year from $108000.0 in Q1 2025.
Akari Therapeutics' Short-Term Debt repayments history runs 3 years deep, the most recent figure standing at $102000.0 for Q1 2026.
- In Q1 2026, Short-Term Debt repayments fell 5.56% year-over-year to $102000.0; the TTM figure through Mar 2026 stood at $493000.0 (down 50.6% YoY), while the FY2025 annual figure was $499000.0, down 54.84% from the prior year.
- Short-Term Debt repayments came in at $102000.0 for Q1 2026 at Akari Therapeutics, up from $57000.0 in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $336000.0 in Q3 2024 to a low of $57000.0 in Q4 2025.
- A 3-year average of $189555.6 and a median of $169000.0 in 2025 frame the typical range for Short-Term Debt repayments.
- Across the five-year window, Short-Term Debt repayments sank 74.44% in 2025 and slipped 5.56% in 2026, its largest moves.
- Akari Therapeutics' Short-Term Debt repayments stood at $223000.0 in 2024, then plunged by 74.44% to $57000.0 in 2025, then jumped by 78.95% to $102000.0 in 2026.
- According to Business Quant data, Short-Term Debt repayments over the past three periods registered $102000.0, $57000.0, and $169000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Dec 31, 2024 | 223,000.00 |
| Dec 31, 2024 | 223,000.00 |
| Sep 30, 2024 | 336,000.00 |
| Sep 30, 2024 | 336,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Mar 31, 2024 | 215,000.00 |
| Mar 31, 2024 | 215,000.00 |